NCT03844490

Brief Summary

The timing of umbilical cord clamping has been widely discussed in the scientific community. As part of the worldwide strategies to reduce childhood iron deficiency anemia, the incorporation of late clamping (at least one minute after delivery), has been adopted as an effective and low-cost measure for health services. The optimal timing for clamping, ( if until 3 minutes of delivery, or later, when the cord stops spontaneous pulse), still remains controversial. Also, doubts remain about the effect of late clamping of the umbilical cord on maternal outcomes. This study has the hypothesis that waiting for the cessation of the cord pulsation will not bring harm to the newborn or the mother.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
580

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 14, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 18, 2019

Completed
1 month until next milestone

Study Start

First participant enrolled

April 1, 2019

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 2, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 23, 2020

Completed
Last Updated

April 1, 2026

Status Verified

March 1, 2026

Enrollment Period

8 months

First QC Date

February 14, 2019

Last Update Submit

March 26, 2026

Conditions

Keywords

Postpartum HemorrhageNeonatal jaundiceUmbilical cord

Outcome Measures

Primary Outcomes (2)

  • Neonatal Hyperbilirubinemia requiring phototherapy

    clinical situation where hyperbilirubinemia indicates phototherapy. The need for phototherapy will be identified from the analysis of the laboratory results of total bilirubin, applying the values established by the American Academy of Pediatrics (AAP).

    24 to 7 days after birth

  • Neonatal hemoglobin concentration 24-48 h postpartum

    expressed the concentration of neonatal hemoglobin, collected between 24 and 48 hours postpartum

    24 to 48 hours after birth

Secondary Outcomes (21)

  • Weight of the newborn

    1 hour postpartum

  • Apgar Score in the first and fifth minutes

    5 minutes

  • Skin-to-skin contact

    5 hours

  • Duration of skin-to-skin contact

    5 hours

  • Breastfeeding in the first hour after birth

    1 hour

  • +16 more secondary outcomes

Study Arms (2)

CONTROL

OTHER

In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivery)

Other: CONTROL

CESSATION OF CORD PULSE

EXPERIMENTAL

In this group the umbilical cord will remain unclamped until the spontaneous pulsation stops. At this time, cord clamping will be made.

Other: CESSATION OF CORD PULSE

Interventions

In this group the umbilical cord will remain unclamped until the spontanous pulsation stops. At this time, cord clamping will be made.

CESSATION OF CORD PULSE
CONTROLOTHER

In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivey)

CONTROL

Eligibility Criteria

Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • (pregnant women)
  • Low risk pregnancy;
  • Full-term pregnancy (37 to 42 weeks);
  • Single fetus;
  • Cephalic presentation;
  • Normal birth;
  • Euthocic delivery. (newborns)
  • Live birth;
  • Apgar\> 7 in the first minute and fifth minutes.

You may not qualify if:

  • Early clamping for any reason (indicated by assistant);
  • Instrumental delivery (forceps);
  • Chorioamnionitis;
  • Placental abruption;
  • Prolapse of umbilical cord;
  • Congenital anomaly;
  • Labor analgesia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto Materno Infantil Prof. Fernando Figueira

Recife, Pernambuco, 50.070-550, Brazil

Location

MeSH Terms

Conditions

Postpartum HemorrhageJaundice, Neonatal

Condition Hierarchy (Ancestors)

Obstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesPuerperal DisordersUterine HemorrhageHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsHyperbilirubinemia, NeonatalInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHyperbilirubinemia

Study Officials

  • LEILA KATZ, MD, PhD

    IMIP

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Coordinator of the Obstetrical Intensive Care Unit

Study Record Dates

First Submitted

February 14, 2019

First Posted

February 18, 2019

Study Start

April 1, 2019

Primary Completion

December 2, 2019

Study Completion

January 23, 2020

Last Updated

April 1, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

No: There is not a plan to make IPD available.

Locations